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Abstract
Background: Underserved ethnic minority women experience significant disparities in cervical cancer incidence
and mortality, mainly due to lack of cervical cancer screening. Barriers to Pap smear screening include lack of
knowledge, lack of health insurance and access, and cultural beliefs regarding disease prevention. In our previous
SUCCESS trial, we demonstrated that HPV self-sampling delivered by a community health worker (CHW) is
efficacious in circumventing these barriers. This approach increased screening uptake relative to navigation to
Pap smear screening. SUCCESS trial participants, as well as our community partners, provided feedback that
women may prefer the HPV self-sampler to be delivered through the mail, such that they would not need to
schedule an appointment with the CHW. Thus, our current trial aims to elucidate the efficacy of the HPV self-sampling
method when delivered via mail.
Design: We are conducting a randomized controlled trial among 600 Haitian, Hispanic, and African-American
women from the South Florida communities of Little Haiti, Hialeah, and South Dade. Women between the ages
of 30 and 65 years who have not had a Pap smear within the past 3 years are eligible for the study. Women are
recruited by CHWs and complete a structured interview to assess multilevel determinants of cervical cancer risk.
Women are then randomized to receive HPV self-sampling delivered by either the CHW (group 1) or via mail
(group 2). The primary outcome is completion of HPV self-sampling within 6 months post enrollment.
Discussion: Our trial is among the first to examine the efficacy of the mailed HPV self-sampling approach. If
found to be efficacious, this approach may represent a cost-effective strategy for cervical cancer screening within
underserved and underscreened minority groups.
Trial registration: ClinicalTrials.gov, NCT02202109. Registered on 9 July 2014.
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Background
Widespread adoption of the Pap smear has significantly
reduced cervical cancer incidence and mortality in the
US [1]. However, not all US women have benefited
equally. Minority, low-income, and underinsured women
remain at excess risk of being diagnosed with and dying
from cervical cancer [2–4]. This disparity is particularly
problematic in light of the enormous financial, quality of
life, and emotional burden associated with cervical can-
cer management. In 2010, the estimated annual net cost
of cervical cancer treatment during the initial treatment
phase was projected to be US$54,209 for women aged
under 65 years and US$45,174 for women aged 65 years
and older [5]. Quality of life in cervical cancer patients is
often impacted by increased depression, anxiety, fear,
distortion of body image, diminished self-perceived
femininity and self-esteem, and sexual and reproductive
issues [6]. In Miami, FL, cervical cancer is a particular
problem for Haitian and Caribbean Hispanic women.
When compared to other racial/ethnic minority and
immigrant groups in the Miami metropolitan area, Hai-
tian and Hispanic women contribute disproportionately
to cervical cancer incidence, morbidity and mortality,
largely as a function of their underutilization of Pap
smear screening [7–10]. They do not receive routine
Pap smears for myriad reasons including but not lim-
ited to: poverty, language difficulties, limited access to
health care, lack of knowledge about cancer and the im-
portance of early detection, cancer fatalism or the belief
that cancer implies death, and cultural norms about
health and about disease prevention [7, 11–18].
Alternative screening strategies, such as human papil-
loma virus (HPV) self-sampling, may circumvent the
aforementioned barriers to cervical cancer screening
within these groups [19]. Briefly, HPV self-sampling
enables women to test themselves for HPV outside a
clinical setting, and has consistently been shown to be as
sensitive as physician-collected specimens for HPV
detection [20]. HPV testing examines the presence of
high-risk HPV, the primary cause of cervical cancer,
while Pap smear screening examines the presence of
precancerous cell abnormalities. While not the current
standard-of-care for cervical cancer screening, HPV test-
ing has demonstrated superior sensitivity and negative
predictive value when compared with Pap smear screening
[21]. In other countries, randomized studies of HPV
self-sampling have shown increased rates of screening
[19, 22]. In the US, nonrandomized studies have also
shown that this approach has high acceptability among
minority women [19, 23].
We have recently completed a randomized controlled
trial of community health worker (CHW)-delivered,
home-based HPV self-sampling among Haitian and
Hispanic immigrant women living in South Florida,
through our National Cancer Institute (NCI)-funded
South Florida Center for Reducing Cancer Disparities
(SUCCESS) [24]. When compared with both standard
educational outreach, as well as CHW-guided naviga-
tion to Pap smear screening, HPV self-sampling was
superior in increasing cervical cancer screening uptake.
Given that HPV self-sampling has been shown to be the
superior method of cervical cancer screening within
our target communities, our focus has shifted to under-
standing how best to implement self-sampler delivery.
Participant feedback from our SUCCESS trial indicated
a possible preference for a mailed approach, which
would eliminate the need for a CHW to visit partici-
pants’ homes to deliver the self-sampler. Given our re-
sults, as well as our participant feedback, for the
current trial we are examining the efficacy of a mailed
HPV self-sampling approach versus home-based HPV
self-sampling delivery in increasing cervical cancer
screening uptake among immigrant women living in
South Florida.
Aims and objectives
As in our prior trial, our first aim is to examine uptake
of cervical cancer screening by women assigned to HPV
self-sampling via mail versus home-based HPV self-
sampling delivered by a CHW. Our second aim is to
examine the efficacy of these interventions by site, ethnic
group, and acculturation level. Finally, we aim to examine
the impact of these interventions on secondary outcomes
including knowledge, attitudes, and beliefs about cervical
cancer and the importance of early detection of disease
and access to care, as well as to determine the relative cost
of the two intervention strategies. Ultimately, our trial will




We are recruiting 600 women from three South Florida
immigrant communities: Little Haiti, Hialeah, and South
Dade. Minority women aged 30–65 years who have not
undergone cervical cancer screening in the past 3 years
are recruited to participate by a CHW, based at a part-
ner organization in their community of residence.
Women who agree to participate will have a 30-min
interview in their home by one of our two bilingual
Community Health Educators (CHEs). Upon comple-
tion of the interview, participants are randomized into
one of two interventions. The CHW self-sampling
intervention is our control arm (CHW+ SS). Women
randomized to this arm receive a home visit by a CHW,
who provides education about cervical cancer and the
importance of early detection of disease, as well as de-
tailed instruction for how to self-sample for HPV. In
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comparison, women in our experimental arm (SS +M)
receive the self-sampler by mail along with print mater-
ial that provides information about cervical cancer and
instructions for using the self-sampler. The study pro-
cedure timeline is outlined in Table1 and page listings
for all study components can be found in our Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Checklist (see Additional file 1).
Our study occurs in three South Florida immigrant
communities: Little Haiti, Hialeah, and South Dade.
More than 100,000 Haitian immigrants are known to
reside in Little Haiti, though the actual number may ex-
ceed 250,000 [25, 26]. The majority of Little Haiti resi-
dents were born in Haiti and speak a language other
than English at home [7]. The median household income
in the seven census tracts that comprise Little Haiti is
US$21,646 and 45% of the population lives below the
federal poverty limit [26]. Over two thirds of the adult
population in Little Haiti does not have a high school
diploma or GED [26]. Little Haiti is a federally desig-
nated Medically Underserved Area/Population (MUA/P)
and Health Provider Shortage Area [27]. Access to care
in this neighborhood may be complicated by limited
health insurance coverage (only 40% of residents were
covered prior to the Affordable Care Act), immigration
status and fear of deportation, and limited proficiency in
English and/or Spanish, the primary languages spoken in
Miami, FL [28].
Our second community, Hialeah, is located in Miami-
Dade County and is part of the Miami metropolitan
area. It is a historic ethnic enclave comprised largely of
Cuban immigrants and Cuban Americans who represent
74% of the community’s 232,311 residents [29]. The
median household income in Hialeah is US$33,942 and
26% of residents live below the federal poverty threshold
[29]. Twenty-nine percent of adults in Hialeah do not
have a high school diploma or equivalent [29]. A vast
majority (91%) of adults speak Spanish at home [29].
English language proficiency is limited for many, which
constitutes a barrier to seeking timely cancer and control
prevention information, including information about
routine screening [24–29].
The community of South Dade is located just south of
Miami and has a total population of 208,491 [26]. Ap-
proximately 22% of residents identify as Black. The eth-
nic make-up of South Dade is primarily Hispanic (63%)
of diverse national origins (e.g., 46% Cuban, 26% Central
or South American, 10% Puerto Rican, 4% Dominican,
and 13% Mexican) [26]. South Dade is a low-income
area, with a median household income of approximately
US$45,322; nearly a quarter (23%) of residents live below
the federal poverty threshold [26]. South Dade is also a
federally designated health provider shortage area, as
well as a designated Medically Underserved Area/Popu-
lation (MUA/P) [27].
As indicated by the sociodemographic profiles of these
three communities depicted in Fig. 1, poverty, low edu-
cational attainment, limited English language proficiency
and limited access to care represent major challenges to
public health initiatives that target cancer prevention.
Additionally, sociopolitical histories that include dis-
crimination and longstanding linguistic isolation further
complicate access to routine cervical cancer screening by
fostering communitywide distrust of medical authorities
and research in general [7, 24]. Such distrust necessitates
a responsive approach that works within the particular so-
ciopolitical, linguistic, and cultural frameworks of these
communities to promote cancer prevention [7, 24]. This
Table 1 Schedule of enrollment, interventions, and assessments
Recruitment Enrollment Allocation Intervention Exit
Time point −t2 −t1 0 t1 t2
Enrollment:





CHW + SS X
SS +M X
Assessments:
Cervical cancer screening X X
Sociodemographic and psychosocial characteristics X X
Cervical cancer knowledge, access to care, knowledge and follow-up of test results,
acceptability of screening delivery
X X
CHW + SS CHW self-sampling intervention, SS + M Self-sampling by mail
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approach thus demands guidance and collaboration with
community partners from each site, as is consistent with
community-based participatory research (CBPR).
Conceptual approach
Our approach is driven by Social Ecological Theory,
which postulates the interaction between larger systemic
factors (relationships, communities, culture, etc.) and
individual factors influence health behavior [30]. Given
this approach we recognize that the aforementioned
barriers to cervical cancer screening among immigrant
women exist not only on the individual level, but also on
the larger systemic, cultural, and community levels; our
approach aims to engage each of these levels. Thus, the
development, design, and implementation of our study is
guided by the principles of CBPR. CBPR engages com-
munities at these multiple levels of influence through
partnerships with key community stakeholders which in-
form the development of culturally-sensitive interventions
and initiatives. Ultimately, through these partnerships
CBPR allows for the dissemination of intervention not
only at the individual but also at the community level.
Prior to the SUCCESS trial, we developed campus-
community partnerships with key community stake-
holders in each of our target communities (Little Haiti,
Hialeah, and South Dade) [7]. With these stakeholders, as
well as with key community members, we formed Com-
munity Advisory Groups (CAGs) within each of the com-
munities. These groups guided the goals, scope, and
development of our prior SUCCESS trial as well as the
current study, providing critical input at each step of the
work from design to dissemination. Moreover, Health
Choice Network, a federally-qualified health care center
and one of our key community partners, is subcontracted
on the study to hire and manage CHWs, as well as to pro-
vide any necessary follow-up care for study participants.
Community health worker training
In response to the historical distrust of “outsiders” by
community residents, key community leaders in Little
Haiti, Hialeah, and South Dade suggested that study data
should be collected by CHWs who are indigenous to the
neighborhoods and knowledgeable about community
norms and customs. Each community site employs and
supervises one CHW. CHWs must be Hispanic or
Haitian, have graduated from college, and speak English
and Haitian Creole or English and Spanish fluently.
The principal investigator (PI) along with key commu-
nity partners developed formalized in-person research
training for the CHWs. The training was provided by
the study manager. This training is based on the princi-
ples of participatory learning and adult education, and is
organized into four modules. The first session covered
the epidemiology of cervical cancer, and introduced the
CHWs to study aims and their role in accomplishing
such aims. The second session taught the CHWs about
the principles of research ethics, and helped them to
complete the University of Miami’s certification course
(CITI) for conducting human subject research. The third
and fourth sessions provided rigorous instruction on re-
search methodology and collecting study data. As part of
these sessions, the CHWs formally practiced and received
feedback on their interviewing and teaching skills.
Eligibility
Inclusion criteria
To be eligible women must be: (1) Haitian, Hispanic or
African American, (2) aged 30–65 years, (3) report not
Fig. 1 Cervical cancer incidence and sociodemographic characteristics in intervention communities
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having had a Pap smear in the last 3 years, and (4) live
in the neighborhoods of Miami/Little Haiti, Hialeah or
unincorporated Southern MiamiDade. Women under
the age of 30 years have a high false-positive HPV rate
due to transient HPV infections. Thus, the HPV test is
not recommended for that age group [31, 32]. Our older
age cutoff of 65 years is based on the Unites States
Preventive Services Task Force (USPSTF) cervical cancer
screening recommendations [33].
Exclusion criteria
Women are not included in the study if they: (1) report
having had a hysterectomy, (2) have a history of cervical
cancer, (3) plan to move out of the neighborhood during
the 6 months after enrollment, and/or (4) are enrolled in
any other cancer prevention/outreach-related study.
Allocation of trial interventions
Once participants complete the enrollment interview,
they will be randomized into one of two possible inter-
ventions. This randomization will be done by the study
biostatistician, using REDCap’s randomization module.
This module allows for the electronic randomization of
study participants to study arm, with the option of ran-
domizing within study sites to account for nesting. As
our study design is hierarchical, with each subject nested
within a site, the randomization is based at the site level
(i.e., participants will be randomized within site). Once
randomization is completed, the CHWs are notified by
an automated email generated by REDCap. The CHWs
then follow up with the women within a week, inform
them of their assignment and, if in the control arm
(CHW+ SS), schedule the home visit. The CHE who
conducts the enrollment and 6-month follow-up visit is
blinded to participant group assignment. Both the
CHWs and the participants are aware of study arm
assignment.
Recruitment
Recruitment occurs at various community venues, in-
cluding laundromats, churches, health clinics, and flea
markets throughout Little Haiti, Hialeah, and South
Dade. The CHWs also rely heavily on their own social
networks and those of the community leaders, active in
SUCCESS CAGs, to identify potentially eligible partici-
pants. Our preliminary research in Little Haiti and
Hialeah indicates that random recruitment strategies
engender suspicion and compromise overall participa-
tion. As a result, we must employ a nonprobability,
purposive quota-based sampling strategy to recruit par-
ticipants. We will compare study samples with data ab-
stracted from the US census to better understand
whether our sample is, in fact, representative of our target
communities. The CHW will approach potentially-eligible
individuals at community venues, introduce themselves,
and explain their role as a CHW. They will then inquire
if a potential participant has recently been screened for
cervical cancer, and if not, if they would be interested in
participating in a study. The CHWs then screen inter-
ested potential participants for eligibility, and for those
women who screen eligible, the CHW further describes
the study. For eligible and interested women, the CHW
tries up to ten times to reach a potential participant over




For this study, we plan to use a self-sampling device de-
veloped by Preventive Oncology International (POI) and
the National Institutes of Health (NIH). The POI/NIH
self-sampler is 20 cm in diameter, which is similar to a
regular-sized tampon. This sampler is easy to use. A
woman inserts the device into her vagina until she feels
slight resistance, exposing the collection swab tip to the
cervix. The participant then holds the paddle end of the
collection swab and rotates it three times. She then with-
draws the collection swab. Once the collection swab is
fully removed from the vagina, the participant (or health
worker) places the collection swab into liquid cell pre-
servative. HPV testing can be effectively performed on
this single specimen. Consistently this device has been
found to be just as sensitive as a physician-performed
test for detecting HPV and, in some instances, cervical
dysplasia [20, 21].
Intervention group 1—CHW-delivered HPV self-sampling
(CHW + SS)
In general, the intervention strategy involves two over-
lapping domains: (1) health education on cervical cancer
screening and (2) instructing women about how to
appropriately self-sample. They are also advised that if
HPV obtained through self-sampling is positive, they will
need follow-up medical care at our clinical sites. The
CHWs stays with a woman (not in the same room) as
she self-samples in order to answer any questions that
may arise during the process. The samples can be stored
at room temperature and are delivered once a week to a
CLIA-approved laboratory for testing (APTIMA HPV
Assay; GenProbe Inc.). Women who choose not to self-
sample are provided with information about our com-
munity partners and other local resources where they
can get a free and/or low-cost Pap smear.
Intervention group 2—mailed HPV self-sampling
Within 1 week after completing the interview, women
randomized to the intervention arm receive a self-
sampling kit via mail. This kit includes: (1) the self-
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sampler, (2) the vial for collecting and storing the
specimen, (3) a preaddressed, stamped envelope for
returning the vial to the CLIA-approved laboratory for
HPV testing (see above), (4) a brief introductory letter
which includes a picture of the CHE and the CHW and
serves to reorient the participant to the focus of the
study, (5) a brochure containing the same images that
CHWs present to control group participants during
home visits, that visually depict the steps for self-
sampling (see Additional File 2), (6) NCI pamphlets
about cervical cancer and the importance of early de-
tection of disease in the participant’s language of pref-
erence (identified at enrollment), and (7) information
provided by our community partner in each site about
their organization, the medical services provided, and
how to schedule a Pap smear. We are intentionally not
having the CHW formally contact intervention partici-
pants before the 6-month mark to avoid unduly influ-
encing their decision to self-sample. However, we are
having the CHW make one phone call a week after the
self-sampling kit has been mailed to confirm that the
participant did, in fact, receive it.
Community health workers
In response to the historical distrust of “outsiders” by
community residents, key community leaders in Little
Haiti, Hialeah, and South Dade suggested that study data
should be collected by CHWs who are indigenous to the
neighborhoods and knowledgeable about community
norms and customs. Each community site employs and
supervises one CHW. CHWs must be Hispanic or Hai-
tian, have graduated from college, and speak English and
Haitian Creole or English and Spanish fluently.
The PI along with key community partners developed
formalized in-person research training for the CHWs.
The training was provided by the study manager. This
training is based on the principles of participatory learning
and adult education, and is organized into four modules.
The first session covered the epidemiology of cervical can-
cer, and introduced the CHWs to study aims and their
role in accomplishing such aims. The second session
taught the CHWs about the principles of research ethics,
and helped them to complete the University of Miami’s
certification course (CITI) for conducting human subject
research. The third and fourth sessions provided rigorous
instruction on research methodology and collecting study
data. As part of these sessions, the CHWs formally prac-




The interview is conducted by our CHEs to avoid intro-
ducing bias into our study design. Prior to beginning the
interview, the CHE first conducts another eligibility
screen to verify that the potential participant still meets
study eligibility criteria. The CHE will then explain for a
second time the study to the potential participant and
answer any questions she may have. If she is still agree-
able to participating, the CHE obtains signed informed
consent. After obtaining consent, the CHE proceeds
with the interview (see Additional File 3). This interview
is conducted using laptops with access to the REDCap
web-based platform (see below). Backup paper copies
are available in case the CHE experiences difficulty
accessing the web.
Given widespread skepticism about research in our
target communities, the need for brief measures has
been one of the most important lessons we have learned
from our experiences with participants. Thus, our inter-
view is no more than 30 min in length. Our top priority
is to collect data related to our primary outcome vari-
able, cervical cancer screening. The second priority is
to collect data on potential confounders that we may
need to adjust for. Our third priority is to collect data
on additional outcomes via our enrollment and exit
questionnaires, including access to care, and cervical
cancer knowledge, attitudes, and beliefs. Our interview
draws from previously-validated scales, as well as our
ongoing research with the target communities. Though
originally conceived in English, we translated the ques-
tionnaire from English to Haitian Creole and Spanish,
as well as tailored questionnaire items based on com-
munity feedback.
Follow-up interview at 6 months
At 6 months post enrollment, the CHE completes a
follow-up interview with the participant (see Additional
File 4). The follow-up interview contains the same con-
tent as the enrollment interview, with the addition of
self-sampler acceptability items for those who have com-
pleted screening. The CHW schedules the follow-up
interview with the CHE.
Participant timeline
We began enrollment in month 3 and will end enroll-
ment by month 27 of our 36-month study (see Add-
itional File 5). Thus, our recruitment goal is 10–12
women/month per site (30–36 women/month total).
These assumptions are based on our prior experience
with our SUCCESS trial where we recruited nearly 12
women/month at each site on average.
Outcome measures
Primary outcome
Our primary outcome will be completion of HPV self-
sampling within 6 months post enrollment. Using an
intent-to-treat approach, we will assume that any
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women who are lost-to-follow-up did not complete
cervical cancer screening.
Secondary outcomes
We also plan also to examine several secondary outcomes,
including: (1) access to care (health insurance, having a
usual source of care, and whether there has been a visit to
a provider in 6 months), (2) cervical cancer knowledge, at-
titudes, and beliefs (measured using our initial and exit
questionnaires developed in collaboration with commu-
nity partners), (3) knowledge of test results and, for those
with an abnormal screen, the proportion of women in
each group who received appropriate follow-up within
30 days of the abnormal screen, and (4) acceptability of
screening delivery.
Sample size calculation
We based the proposed sample size on our work with
our previous trial, SUCCESS. As previously mentioned,
CHW with self-sampling (CHW+ SS) was one of the
study arms in that trial’s three-armed randomized
study. Approximately 90% of women randomized to
our CHW+ SS arm complete screening as compared to
47% of women who receive CHW education and navi-
gation to Pap smear screening. In the proposed study,
we will introduce self-sampling through mail (SS +M)
and compare screening uptake between this approach
and CHW+ SS.
With these considerations, the sample size was chosen
to ensure sufficient power (80%) to detect clinically
meaningful effects associated with a 20% point increase
in proportion screened in the SS +M intervention group
versus CHW+ SS at an alpha of 0.05. The calculations
performed indicate that the proposed total sample size
of 600 women (i.e., 200 women at each site) will provide
sufficient power for the main study hypotheses, under a
variety of assumptions.
Fidelity
We will assess intervention fidelity across each commu-
nity through ongoing review of CHW participant encoun-
ter logs, which provide detailed process data regarding
intervention delivery. Any identified inconsistencies in
study implementation will be systematically documented,
as well as addressed as part of ongoing team meetings.
We will examine participant HPV knowledge post inter-
vention as an additional measure of intervention fidelity,
and also conduct a cost analysis. The observed differences
in the cost of one arm relative to the other is necessary to
inform future implementation and dissemination.
Withdrawal of participants from study
Any participant may choose to withdraw from the
study at any time. If a participant chooses to withdraw,
their data will be destroyed, and their reason for with-
drawal recorded. Participants may withdraw by con-
tacting the CHE.
Data management
All study data collected will be uploaded into the RED-
Cap system. As previously stated, CHEs have access to
this system to enter participant data in real time. RED-
Cap is a web-based research management application
that is designed specifically for investigators and their
research teams. It supports processes for patient re-
cruitment, scheduling, budgeting, invoicing, milestone
management, data safety monitoring, adverse event
reporting, system integration, data collection, and study
execution. It is easy to use, reliable, fully HIPAA-
compliant, and completely secure. CHEs responsible for
data entry will be immediately notified, in REDCap, of
missing fields and improbable values when entering data.
Furthermore, quality and completeness of data entry will
be systematically checked by a data manager at regular
intervals for the duration of the study. Only the study
statistician has access to the raw data files entered by
CHWs. De-identified data files that have been cleaned
and appropriately grouped and categorized will be made
available to study personnel requesting such data.
Statistical analysis
All of the statistical analyses will be carried out using
SAS for Windows (Cary, NC, USA), Splus (Insightful,
Inc.) for Windows, and SPSS for Windows. Initially, we
will perform an exploratory data analysis and calculate
descriptive statistics. Intent-to-treat analyses to examine
uptake of cervical cancer screening will be conducted.
All women who were randomized will be included in
these analyses, and any participant who is lost-to-follow-
up will be assumed not to have completed the cervical
cancer screening. Associations between covariates and
group assignment will be evaluated via logistic regres-
sion. Any covariates differing significantly between study
groups will be controlled for when evaluating the associ-
ation between group assignment and screening uptake
via logistic regression.
Subgroup and secondary outcome analyses
We have several planned subgroup analyses to help us
understand whether our intervention was more effective
among certain population subgroups. We therefore
propose to examine differences by site, ethnic group,
education level, health insurance status, and acculturation
level. To evaluate subgroup differences, we will model in-
teractions between these variables and study group assign-
ment, and present stratified analyses for those variables
with significant interactions. For example, we will test
whether the intervention effect differs across sites by
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modeling an interaction between site and group assign-
ment, then stratify our primary analyses by study site if
the interaction is significant in order to examine differ-
ences between study arms regarding cervical cancer
screening uptake. We also plan to examine the change
in several secondary outcomes, described previously,
within the overall sample, as well as between study
groups via repeated measures analysis of variance
(ANOVA).
Cost analyses
As an additional secondary aim, we will estimate the
cost of providing the intervention. From this, we can
determine the additional cost of screening one woman
in the SS +M as compared to the control arm (CHW
+ SS); this cost may be positive or negative. To do
this, we will first estimate the total cost of providing
the intervention arm to the 200 women recruited into
that arm. We will then divide the total cost of that
arm by the number of women screened to get a “cost
per woman screened” for each of the arms. To calcu-
late a total cost for each arm, we will collect resource
utilization information on all aspects of the program.
Using a comprehensive data collection form that we
will develop in the first months of the program, we
will collect information on all resource use that oc-
curs during the intervention. Information that is col-
lected includes: (1) personnel time: this includes
personnel time that is devoted to training the CHEs
and CHWs, assessing eligibility, managing contacts,
and recruiting, conducting the intervention, and ad-
ministrative time. We will not include the time that
is spent on research activities, as this would not be
applicable to a nonresearch community-based inter-
vention, (2) space: we collect information on space
used for the delivery of the intervention (where ap-
plicable) and administrative space, (3) supplies: we
collect information on all supplies that are needed
(e.g., the NCI pamphlets for both arms, mail costs),
and (4) medical care: we have information on number
of self-samplers analyzed and Pap smears completed.
Data monitoring
We perform primary outcome analyses every 6 months
and report our findings to the NCI. Additionally, all
study staff and the PI meet monthly to review study pro-
gress, as well as any adverse events and feedback from
participants regarding study procedures. Moreover, we
have developed quality control procedures to monitor all
aspects of study implementation. Finally, study data is
reviewed on a regular basis to ensure proper entry and
storage procedures.
Reporting and dissemination
Protocol approvals and amendments
The current study was approved by the University of
Miami Institutional Review Board. There have been
12 minor amendments to update the study docu-
ments, as well as staff added to the protocol (version
date: 21 June 2016).
Informed consent
As previously mentioned, two bilingual (English/Creole,
English/Spanish) CHEs obtain informed consent in the
participant’s preferred language (the Informed Consent
Document is translated into Spanish and Haitian Creole).
If a potential participant cannot read, the CHE reads the
Informed Consent Document aloud to her, with a witness
to ensure no bias in the consent process. CHEs answer all
participant questions prior to obtaining their signatures.
Confidentiality
All participants are assigned a study ID number and study
interview documents and datasets will be de-identified.
Only study staff have access to the document that links
study ID with participant names. All paper files are stored
in locked file cabinets within secure office spaces. All elec-
tronic files are stored on secure servers on password-
protected computers.
Financial interests
All of the study team members, as well as the study staff,
have no financial interests to disclose.
Access to data
Only the data manager and study biostatistician have access
to raw data files. The data manager may grant other study
staff access to cleaned and de-identified datasets if needed,
as well as generate tables and charts for ongoing data
analysis and monitoring. Outside investigators may request
access to de-identified datasets through the study PIs.
Post-trial care
For all women who remain unscreened at the 6-month
follow-up, CHWs offer another opportunity to self-
sample and/or linkage with a Pap smear provider, based
on the preferences of the participant. All participants
who screen positive for HPV are referred to low-cost fol-
low-up care by the CHWs. CHWs will navigate partici-
pants who screen positive for HPV to one of our low-
cost community health care providers, and follow-up
with participants to ensure that appointments have
been made and attended. These health care providers
will determine the follow-up care (e.g., Pap smear, col-
poscopy) to be provided to participants.
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Dissemination
In addition to disseminating our findings through jour-
nals, conferences, and other standard academic channels,
our community partners will oversee the dissemination of
research findings within our target communities. Within
the community setting, we will disseminate findings
through culturally appropriate communication channels,
including local radio and by organizing a series of com-
munity forums.
Discussion
Our project addresses the excess burden of cervical cancer
experienced by Little Haiti, Hialeah, and South Dade, three
medically underserved communities within the Miami
metropolitan area [2–14]. Using a CBPR approach, we will
determine the efficacy of CHW versus mail-delivered HPV
self-sampling among 600 women from our target commu-
nities. Study findings will allow us to optimize this for cer-
vical cancer screening in real-world settings.
The current study is not without methodological limi-
tations, however. The use of one CHW per site may
impede our ability to determine whether differences in
study outcomes between our communities are attribut-
able to community versus CHW-related factors. As such,
we employ quality control measures to ensure study
fidelity and optimize reliability among our CHWs.
Additionally, we collect data on each interaction that
CHWs have with participants (including phone calls),
to better understand the potential impact of CHW-
related factors on study outcomes.
Additionally, while HPV testing has been shown to
demonstrate greater sensitivity and negative predictive
value than the Pap smear, it is not yet standard-of-care
practice for primary cervical cancer screening [21].
However, our prior work indicates that many women
within our target communities experience significant
barriers to Pap smear screening that may be circum-
vented by HPV self-sampling. While the USPSTF does
not yet recommend HPV self-sampling as the “gold
standard” method, it does recommend the use of this
method among hard-to-reach populations [33]. In our
previous SUCCESS trial, many women who were not
amenable to Pap smear screening elected to self-sample,
and through their engagement with our study, eventually
were able to connect with the formalized health care sys-
tem. As with our prior trial, all women in the current
study are given information and referrals to community
health centers where they may receive low-cost Pap
smear screening.
Trial status
As of 25 August 2016, we have enrolled 571 of our
target 600 participants in the study.
Additional files
Additional file 1: SPIRIT Checklist (.docx): page listings for all SPIRIT
study components. (DOC 122 kb)
Additional file 2: Self-sampling instructions. (PDF 100 kb)
Additional file 3: Enrollment questionnaire. (DOCX 480 kb)
Additional file 4: Exit questionnaire. (DOCX 232 kb)
Additional file 5: Trial flow diagram. (DOCX 153 kb)
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